Allergic or hypersensitivity reactions, including anaphylaxis, reported. Arrhythmia, pulmonary edema, and cardiac arrest reported (caution if history of atrial arrhythmia; may cause serious fluid retention; use cautiously in conditions where expansion of plasma volume should be avoided). Dose-limiting papilledema, more frequently associated with use in children, occurred (use with caution in pre-existing papilledema or with tumors involving CNS; patients experiencing oprelvekin-related papilledema have higher risk for visual acuity changes). Use with caution in pre-existing pericardial effusions or ascites, in hepatic/renal impairment, in respiratory disease, and in history of stroke or thromboembolic problems. Not indicated following myeloablative chemotherapy (higher risk of toxicity). Closely monitor fluid and electrolytes in patients on chronic diuretic therapy (severe hypokalemia may contribute to sudden death). May produce decreases in hemoglobin concentration, serum concentration of albumin and other proteins (result of expansion of plasma volume).